Enterprise Value

30.33M

Cash

492M

Avg Qtr Burn

-59.56M

Short % of Float

27.26%

Insider Ownership

29.44%

Institutional Own.

98.59%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ALLO-501A (CD19) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Update

ALLO-316 (CD70) Details
Solid tumor/s, Renal cell carcinoma, Cancer

Phase 1

Data readout

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

ALLO-605 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update